Table 1.

Clinical safety and efficacy systemic review.

Author (Year)	Groups Studied and Intervention	Results and Findings	Conclusions
Study 1: Husni [23]	Adults ≥ 18 with active PsA for ≥ 6 months were given either 2 mg/kg IV golimumab or placebo at weeks 0 and 4 and every 8 weeks.	A greater percentage of patients in the treatment group reached ACR20, ACR50, and ACR70. Radiographic progression was also significantly improved.	Golimumab was found to be significantly effective in treating patients with active PsA after 1 year. Although there were increased AEs, they were like those of other anti-TNF agents.
Study 2: Ruperto [27]	Active pc-JIA, ages 2–17, 80 mg/m2 golimumab. Weeks 0 and 4 and weeks 8 through 52, with methotrexate after week 28.	JIA ACR 30, 50, 70, 90 response rates for 84%, 80%, 70%, and 47% at week 28 and through to week 52; 6% with serious infections, including one death caused by sepsis.	Golimumab was effective in treating pediatric patients with pc-JIA. Serious AEs (infections) occurred in 6%., with one death.
Study 3: Lanz [28]	Ten (seventeen eyes) females ages 7–21 with active JIA-associated uveitis refractory to adalimumab received golimumab.	Eight patients with loss of response all responded to golimumab. The 2 initial non-responders did not respond to golimumab.	Golimumab is therapeutic in patients with loss of response to adalimumab, but those not responding to adalimumab did not respond to golimumab.
Study 4: Brunner [29]	In total, 173 active polyJIA patients ages 2–17 were treated with golimumab or a placebo.	After 48 weeks, there was no difference in the number of JIA flareups and clinical remission between golimumab and placebo. Golimumab was safe and tolerated well.	Golimumab resulted in significant improvement in patients with active polyJIA; however, primary endpoints were not met.